ArTiMist has actually been tested on kids with severe malaria and it works - and seemingly it works well.
Our investment in the company has been significantly de-risked IMO. They actually have a unique product that can deliver meaningful results and earn income.
So, we need a further trial. We should have all known that 30 patients was not adequate sample size. Better to do this right - which they are doing.
EMS Price at posting:
7.0¢ Sentiment: LT Buy Disclosure: Held
